Find Academic Supervisors

John GriffinView profile

Professor

• Coagulation Pathways
• Neuroprotection
• Thrombosis
• +5 more

John Griffin is a Professor in the Department of Translational Medicine at the Scripps Research Institute. His research focuses on the cytoprotective protein C pathway, coagulation mechanisms, and neuroprotection in ischemic stroke. He holds adjunct professorships in the Department of Medicine at the University of California, San Diego. Education includes a PhD in Biochemistry from Philipps University Marburg (1984) and an M.S. in Biology from Justus-Liebig University of Giessen (1980). Professional experience spans roles at Harvard Medical School, NIH, and the Centre d'Etudes Nucleaires in France before joining Scripps in 1974. Research interests include the structure-function relationships of activated protein C (APC), development of APC variants like 3K3A-APC for clinical trials, and mechanisms of PAR1 and EPCR receptors in anti-apoptotic signaling. His work bridges basic science, preclinical, and clinical studies with translational medicine applications. Key contributions include demonstrating APC's neuroprotective effects in stroke models and identifying protein S as a neuroprotectant with dual anticoagulant and anti-inflammatory roles. Recent studies explore APC's role in mitigating radiation injury and cardiac dysfunction. Awards include the 2005 ISTH Career Achievement Award and leadership roles in NIH review panels. He chairs scientific advisory boards for biotech firms focused on thrombosis therapies.

Dennis WilkeView profile

Researcher

• Environmental Systems Research
• Resource Management
• Sustainability Science
• +3 more

Dennis Wilke is a Researcher in the Resource Management Working Group at the Institute for Environmental Systems Research, University of Osnabrück. His research focuses on environmental systems science, neuroimaging of neurodevelopmental and neurodegenerative disorders, and the application of advanced MRI techniques to study brain structure-function relationships. He leads studies on autism spectrum disorder neurobiology, motor dysfunction mechanisms in dystonia/Parkinson's disease, and environmental enrichment interventions for repetitive behaviors. Expertise: Neuroimaging biomarkers | Cortico-basal ganglia circuits | Neuroplasticity mechanisms Active in mouse model development for movement disorders Key collaborator in transcallosal white matter research Recent work emphasizes translational approaches linking genetic, environmental, and neuroimaging data to understand behavioral and motor impairments. His lab combines advanced diffusion MRI (free water imaging, NODDI), functional connectivity analysis, and behavioral phenotyping across species.

Sara MillerView profile

Assistant Professor

• Genomics
• Behavioral Ecology
• Evolutionary Biology
• +5 more

Sara Miller is an Assistant Professor in the Department of Biology at the University of Missouri - St. Louis, affiliated with the College of Arts and Sciences. She leads the Social Insect Diversity Lab, focusing on the interplay between genomics, behavior, and ecology in shaping biological diversity. Her research primarily investigates primitively eusocial Polistes paper wasps, examining speciation drivers, social behavior's impact on diversification rates, and biodiversity comparisons between social and solitary insects. Methodologies include genome assembly, population genetics, museum collections, and behavioral experiments. 2025: Evolution of cognition in social insects 2025: Genomic architecture and phylogeny 2023: Cooperation and recognition mechanisms 2023: Sex-linked genetic variation 2022: Polistes genome assemblies 2021: Environmental genomics and behavior 2020: Population structure and coevolution The Social Insect Diversity Lab serves as a hub for exploring social insect evolution through modern genomic and ecological approaches. Dr. Miller's work bridges molecular biology with macroevolutionary questions, emphasizing interdisciplinary research across biological scales.

Stephanie ThevesView profile

Researcher

• Structure-learning and neural concept representations
• Neural mechanisms of relational reasoning
• Neuro-cognitive processing mechanisms underlying intelligence

Dr. Stephanie Theves is a Research Group Leader at the Max Planck Institute for Empirical Aesthetics. Her work focuses on understanding the neural mechanisms underlying intelligence, relational reasoning, and concept representation through cognitive neuroscience approaches. Department of Cognitive Neuropsychology Her research explores how the hippocampus and prefrontal cortex encode hierarchical concepts, construct cognitive maps, and support relational memory systems. Key findings demonstrate that neural representations prioritize conceptual relationships over raw feature distances, and that place-cell-like mechanisms in the brain modulate memory organization. Theves' recent publications examine category abstraction, spatial cognition, and beta-band activity modulation through sensory training. Her methodological approach combines neuroimaging with computational modeling to investigate neural processes. As part of the Max Planck Society, her work contributes to foundational knowledge in cognitive neuroscience while intersecting with interdisciplinary research themes in music, language, and computational auditory perception.

• Neuroscience
• Hydrocephalus
• Neuroimmunology
• +4 more

Jaleel Miyan is a Senior Lecturer in Neuroscience at the University of Manchester's Faculty of Biology, Medicine and Health. He holds a PhD in Neurobiology from the University of Glasgow (1982) and a BSc in Biological Sciences from the University of Sussex (1978). He has held a Royal Society University Research Fellowship (1986–1996) and is a Fellow of the Royal Microscopical Society and the Higher Education Academy. He serves as a Visiting Professor at the Institute of Child Health, Lahore. His research focuses on the relationship between neural and immune systems, mechanisms underlying fetal hydrocephalus, and CSF's role in neurodevelopment. He discovered that folate supplementation can prevent fetal hydrocephalus and is advancing clinical trials for this treatment. His work contributes to UN SDGs related to health and education. He has published over 110 articles, including studies on CSF's role in neurodevelopment, folate metabolism in Parkinson's disease, and CSF metabolic errors in neuropsychiatric disorders. Awards include the Casey Holter Essay Prize and an Innovations in Teaching award for problem-based learning. Current projects include Autism@Manchester and research on brain disorders. He actively participates in conferences and has external roles with the Royal Society of Biology and Pakistan's Children's Hospital Lahore.

• DNA Damage Response
• Genome Integrity
• Cancer Biology
• +7 more

Jiri Bartek is a Senior Professor at Karolinska Institutet's Department of Medical Biochemistry and Biophysics, where he leads a research group focused on DNA damage response (DDR) mechanisms and genome integrity. His work bridges basic molecular biology with translational cancer research, investigating how cells maintain genomic stability under genotoxic stress and how dysregulation of these processes contributes to cancer development and treatment resistance. His research interests span DNA repair pathways, replication stress, chromosomal instability, cellular senescence, and ribosome biogenesis. Bartek's laboratory has made significant contributions to understanding how the cell cycle checkpoints, particularly those involving p53 and related pathways, respond to DNA damage. His work has revealed novel mechanisms connecting ribosome biogenesis stress to p53 activation and cancer vulnerability, with implications for developing new therapeutic strategies. Analysis of his recent publications (2023-2025) reveals a strong focus on the intersection of DNA damage response, chromosomal instability, and cancer therapy. His group is particularly investigating how ribosomal DNA damage triggers specific cellular responses, the role of replication stress in tumor evolution, and identifying novel therapeutic targets based on DNA repair deficiencies in cancer cells. A notable theme is the exploration of drug repurposing opportunities, particularly with compounds like disulfiram that target specific vulnerabilities in cancer cells. Fernström Foundation's Great Nordic Prize (2016) Silver Medal of Merits from the Czech Senate (2013) Elected member of the Danish Royal Academy of Sciences and Arts (2012) Novo Nordisk Prize (2003) Elected member of EMBO (2000) Bartek has mentored numerous researchers who have gone on to establish independent careers, including Jirina Bartkova, Bennie Lemmens, and Mikael Lindstrom. His group has secured substantial funding for research on DNA damage response mechanisms and their implications for cancer therapy, including several clinical trials investigating repurposed drugs like disulfiram for glioblastoma treatment. The DIRECT trial (Disulfiram Repurposing In Combination with copper for recurrent glioblastoma Treatment) represents a significant translational effort from his laboratory. His research group maintains strong collaborations with clinical departments at Karolinska University Hospital and international research institutions, facilitating the translation of basic discoveries into clinical applications. The laboratory combines advanced molecular biology techniques with high-throughput screening approaches to identify novel targets and therapeutic strategies for cancer treatment.

Chunming LiuView profile

Professor

• Wnt/beta-catenin signaling
• Cancer biology
• Molecular mechanisms of tumorigenesis
• +12 more

Chunming Liu, PhD, is a Professor in the Department of Molecular and Cellular Biochemistry at the University of Kentucky, with a joint affiliation at the Markey Cancer Center. His research is centered on the molecular mechanisms of Wnt/β-catenin signaling and its crosstalk with other pathways in human cancers, particularly colorectal, gastrointestinal, and lung cancers. Postdoctoral Fellowship, Harvard Medical School, 2003 Ph.D., Purdue University, 1997 B.S., Nankai University, 1988 Dr. Liu’s research focuses on understanding how dysregulation of Wnt signaling contributes to tumorigenesis, with a particular emphasis on β-catenin stabilization and the role of tumor suppressors like KLF4. His lab has identified novel components of the Wnt pathway and developed small-molecule inhibitors for cancer therapy. He collaborates extensively with clinicians and medicinal chemists to translate mechanistic insights into novel therapeutics. The recent publications highlight a strong trend in targeting Wnt signaling through small molecules, epigenetic modulators, and metabolic disruptors. His work spans drug discovery, molecular oncology, and translational models, including zebrafish and xenografts, with applications in colorectal, ovarian, and breast cancers. There is a clear focus on combination therapies and cancer stem cells. While specific scientific awards are not listed, Dr. Liu’s extensive publication record in high-impact journals such as Nature , Cell , PNAS , and Cancer Research underscores his significant contributions to the field. Dr. Liu has advised numerous graduate students and postdoctoral researchers, many of whom appear as co-authors on his publications. His collaborations include grants with the Markey Cancer Center and joint projects in drug development. His lab is involved in both basic mechanistic studies and applied pharmacological research. He leads a multidisciplinary research team that integrates molecular biology, biochemistry, and medicinal chemistry to investigate oncogenic signaling and develop novel anti-cancer agents. His lab collaborates with structural biologists and pharmacokinetics experts, particularly in the development and testing of fluorinated stilbenes and urea-based inhibitors.

Anastasia SobolewskiView profile

Lecturer

• Pharmacology
• Mucosal Immunology
• Cancer Biology
• +8 more

Anastasia Sobolewski is a Lecturer in Pharmacology at the University of East Anglia, affiliated with the School of Chemistry, Pharmacy and Pharmacology and the Molecular and Tissue Pharmacology research group. She is actively accepting PhD students and leads a research program focused on mucosal tissue in the lung and gut. Education: B.Sc. (Hons) in Pharmacology, University of Sunderland (1998) Ph.D. in Cell Biology and Cell Physiology, University of East Anglia (2002) Her research centers on mucosal immunology, epithelial stem cells, and intercellular communication in health, inflammation, and cancer. She employs 3D organoid models, bio-imaging, and molecular techniques to study lung cancer resistance mechanisms and gut barrier regulation. Key topics include tunnelling nanotubes in chemoresistance and immune-epithelial crosstalk in intestinal homeostasis. Her recent publications show a strong trend in cancer signaling, macrophage biology, and chemical probe development, reflecting an interdisciplinary approach bridging pharmacology, immunology, and cell biology. Scientific Awards: No specific awards mentioned in the text. Anastasia Sobolewski supervises multiple PhD and MSc students and has secured research funding from the Wellcome Trust and the Engineering and Physical Sciences Research Council. She is involved in interdisciplinary projects, including one on Raman microscopy and another on brain stem cell function funded by the Royal Embassy of Saudi Arabia. Her lab functions as an active research team focusing on mucosal tissue dynamics.

Renee BouleyView profile

Assistant Professor

• Antibiotic Resistance
• Biochemistry
• Structural Biology
• +4 more

Dr. Renee Bouley is an Assistant Professor at The Ohio State University Marion Campus, Department of Chemistry and Biochemistry. She holds a Ph.D. in Organic Chemistry from the University of Notre Dame (2016) and completed postdoctoral research at the University of Michigan (2016–2019). Her research focuses on antibiotic resistance mechanisms, particularly studying L,D-transpeptidases in carbapenem-resistant Enterobacteriaceae (CRE). Techniques employed include X-ray crystallography, protein expression/purification, and structure-based drug design. Collaborations include projects on DNA repair proteins and cancer-related mutations with faculty on both the Marion and Columbus campuses. Education: Ph.D., Organic Chemistry, University of Notre Dame (2016) Postdoctoral Fellow, University of Michigan (2016–2019) B.S., Chemistry, Grand Valley State University (2010) Research Interests: Antibiotic resistance mechanisms Structural biology of L,D-transpeptidases Cancer-related DNA repair pathways RhoGAP proteins in liver cancer Structure-based drug design Key Awards: Eli J. and Helen Shaheen Graduate School Award (2017) Robert M. Scarborough Graduate Award (2017) Dow Chemical Outstanding Graduate Student Award (2016) Lab Focus: Biochemistry lab at Marion Science and Engineering Building (MSE 110H) Undergraduate research opportunities in antibiotic resistance, DNA repair, and cancer biology Collaborations on DNA repair proteins (e.g., RAD52, PRMT5) and RhoGAP mutations

• Computational Neuroscience
• Mathematical Biology
• Biophysics
• +3 more

Dr. Leiv Øyehaug is an Associate Professor at the Department of Computer Science, Faculty of Technology, Art and Design, Oslo Metropolitan University. His research focuses on computational modeling of biological systems through interdisciplinary approaches combining mathematics and physiology. Neuroglial interactions and ion dynamics Cardiomyocyte calcium handling mechanisms Mathematical modeling of skin pigmentation processes Systems biology approaches to complex physiological phenomena Øyehaug's work spans multiple disciplines with key contributions in neuronal activity modeling, cardiac calcium signaling, and dermal system analysis. He collaborates extensively with physiological research groups while maintaining mathematical rigor in his models. The publications demonstrate a strong focus on using quantitative approaches to understand pathophysiological mechanisms in both neural and cardiac contexts.

Xian-Cheng JiangView profile

Professor

• Lipid Metabolism
• Metabolic Diseases
• Atherosclerosis
• +7 more

Xian-Cheng Jiang, PhD is a Distinguished Professor in the Department of Cell Biology at SUNY Downstate Health Sciences University. With over three decades of research experience, Dr. Jiang leads a laboratory focused on lipid metabolism and its role in various metabolic diseases. His work has significantly contributed to our understanding of phospholipid metabolism and its implications for cardiovascular health. Dr. Jiang's educational background includes: Bachelor of Medical Chemistry from Shanghai Medical University (1981) Master of Biochemistry from Shanghai Medical University (1984) PhD in Biochemistry from SUNY Downstate Health Sciences University (1989) Postdoctoral training at Columbia University (1990-1993) Dr. Jiang's research primarily centers on lipid metabolism and its relationship to metabolic diseases. His laboratory investigates how phospholipid metabolism influences plasma lipoprotein metabolism, cell membrane lipid composition and function, and the development of metabolic diseases including atherosclerosis, metabolic syndrome, obesity, and liver steatosis. His work spans three main areas: sphingomyelin biosynthesis, phosphotidylcholine remodeling, and phospholipid transfer protein function. Through innovative approaches using gene knockout and overexpression models, his research has provided crucial insights into the molecular mechanisms underlying lipid-related disorders. Analysis of Dr. Jiang's recent publications reveals a consistent focus on sphingolipid metabolism, phospholipid transfer proteins, and their roles in cardiovascular and metabolic diseases. His work demonstrates a progression from basic biochemical mechanisms to translational applications, with increasing emphasis on therapeutic interventions targeting lipid metabolism pathways. The research spans molecular, cellular, and whole-animal levels, contributing significantly to our understanding of how lipid metabolism affects human health. Dr. Jiang has received numerous prestigious awards for his contributions to science and education: SUNY Distinguished Professor (2020) The Alfred Stracher Faculty Recognition Award, SUNY Downstate (2018) Excellence in Education Award, SUNY Downstate (2015) SUNY Chancellor's Award for Excellence in Faculty Service (2010) SUNY Promising Inventor Award (2005, 2003, 2002) President Research Award, SUNY Downstate Health Sciences University Throughout his career, Dr. Jiang has mentored numerous graduate students and postdoctoral fellows, contributing significantly to the training of the next generation of scientists in lipid metabolism research. His laboratory has been consistently supported by competitive research grants from the National Institutes of Health and other funding agencies, reflecting the significance and innovation of his research program. Dr. Jiang is also actively involved in scientific review panels and editorial boards, further contributing to the scientific community. Dr. Jiang leads an active research laboratory that utilizes advanced genetic, biochemical, and physiological approaches to study lipid metabolism. His team employs various mouse models including systemic and tissue-specific gene knockouts to investigate the roles of specific enzymes and proteins in lipid homeostasis. The laboratory maintains strong collaborations with other research groups both within SUNY Downstate and at other institutions, fostering a dynamic and interdisciplinary research environment focused on understanding the fundamental mechanisms of lipid-related diseases.

Asher AlbertsonView profile

Assistant Professor

• Stroke Recovery
• Aging and Brain Injury
• Neurocritical Care
• +5 more

Asher Albertson, MD, PhD, is an Assistant Professor of Neurology at Washington University in St. Louis, where he is part of the Section of Neurocritical Care and affiliated with the Hope Center for Neurological Disorders. His research focuses on molecular, cellular, and network mechanisms of cerebral recovery after severe injury, with a special interest in the relationship between normal aging and stroke. Education Fellowship: Neurocritical Care, Washington University in St. Louis School of Medicine, 2020 Residency: Neurology, Washington University in St. Louis School of Medicine, 2017 Medical Degree and PhD in Neurobiology: University of Alabama at Birmingham, 2013 Research Interests Dr. Albertson's laboratory investigates the molecular, neuronal, and network drivers of injury and recovery after ischemic brain injury, with the goal of developing therapeutic interventions to improve outcomes after stroke. Specific areas of interest include: The impact of aging on stroke recovery Altered excitation/inhibition balance in injury and recovery Structural plasticity in cortical remapping Clinical applications of EEG in brain injury Network disruption and epigenetic changes in stroke and aging Research Overview Dr. Albertson's research spans from basic molecular and cellular neuroscience to clinical studies in neurocritical care. His recent work includes studies on aging and stroke, cortical network changes, and the application of single-cell analysis in cerebrovascular research. He uses a variety of techniques including rodent models, histology, viral gene transfer, chemogenetics, and widefield calcium imaging. Laboratory and Collaborations Dr. Albertson leads a laboratory focused on cerebral recovery after injury and maintains active collaborations with other members of the Washington University neuroscience community. His translational research involves using clinical EEG to understand cortical behavior after stroke and predict outcomes in critically ill patients.

Tobias BonhoefferView profile

Professor

• Neuroscience
• Synaptic Plasticity
• Visual System
• +4 more

Tobias Bonhoeffer is Director of the Department of Synapses - Circuits - Plasticity at the Max Planck Institute for Biological Intelligence (formerly Max Planck Institute of Neurobiology) in Martinsried, Germany, and Professor at the Ludwig Maximilian University of Munich since 2002. He also serves as Associate Professor at the Norwegian University of Science and Technology (NTNU) since 2014. His research spans multiple levels of analysis, from molecular studies to systems neuroscience, with a primary focus on synaptic plasticity mechanisms and visual system organization. Born January 9, 1960 in Berkeley, California, Bonhoeffer earned his Physics diploma from Eberhard-Karls University of Tübingen (1984) and completed his neurobiology doctorate at the Max Planck Institute for Biological Cybernetics (1988). His postdoctoral work at Rockefeller University with Amiram Grinvald and Torsten Wiesel (1989-1990) was followed by research with Wolf Singer at the Max Planck Institute for Brain Research (1991-1992). He led a research group at the Max Planck Institute of Psychiatry (1993-1998) before becoming Director at the Max Planck Institute in 1998. Bonhoeffer's lab has made seminal contributions to understanding how synaptic plasticity relates to structural changes in the brain. They demonstrated that growth and retraction of dendritic spines underlies synaptic plasticity, that these structural changes facilitate relearning of previously acquired information, and how experience shapes cortical maps. His current research employs advanced imaging techniques to study neural circuits at unprecedented resolution, examining how visual experience drives representational changes in cortical organization and how these relate to memory processes. Analysis of his recent publications reveals a strong emphasis on mouse visual cortex organization, dendritic spine dynamics, and the relationship between structural and functional plasticity. His work increasingly incorporates computational approaches and advanced imaging methods to bridge cellular mechanisms with systems-level understanding of brain function. Member of the Academia Europaea (2003) Ernst Jung Prize for Medicine (2004) EMBO member (2006) Member of the German National Academy of Sciences Leopoldina (2010) Member of the National Academy of Sciences (NAS) (2020) Bonhoeffer has held significant advisory roles including Governor of the Wellcome Trust (2014-2021) and Scientific Advisor to the Chan Zuckerberg Initiative (since 2016). His lab continues to pioneer new methodologies for studying neural plasticity, with recent work focusing on synaptic changes during learning, structural correlates of memory, and how neural circuits adapt to changing environmental demands in both virtual and real-world contexts. The Bonhoeffer Lab maintains extensive international collaborations and trains the next generation of neuroscientists. Their research program integrates multiple approaches including two-photon imaging, virtual reality behavioral paradigms, and computational modeling to unravel the complex relationship between structural and functional plasticity in neural circuits.

Cristina Fornaguera PuigvertView profile

Professor

• Nanomedicine
• Biomaterials
• Polymeric nanosystems
• +9 more

Dr. Cristina Fornaguera Puigvert is a Full Professor at the Department of Bioengineering within the School of Engineering at IQS (Universitat Ramon Llull), holding the prestigious ICREA Academia award. She coordinates the Degree in Biomedical Sciences since 2022 and leads the GEMAT (Materials Engineering) research group, which operates in three main areas: development of new functional materials, surface engineering, and biomaterials. Her educational background includes a PhD in Pharmacy (2015, UB), a Master's degree in Respiratory Medicine (UB/UPF), and a Graduate degree in Biotechnology (2010, UAB). She has served as a Visiting researcher at i3S, Porto, Portugal (2021) and has been a Hired Professor Doctor since 2018. Dr. Fornaguera's research focuses on polymeric nanosystems for biomedical applications, with particular emphasis on designing advanced drug delivery systems, non-viral gene therapy vectors, mRNA vaccines, and novel immunotherapies for cancer treatment. Her work spans from fundamental nanomaterial science to clinical applications, with significant contributions to vectorizing nanoformulations to specific organs and developing smart nanoparticles for in situ immune cell engineering. She has pioneered approaches for crossing physiological barriers including mucoses, epithelial barriers, and the blood-brain barrier. Her extensive publication record demonstrates consistent innovation across multiple therapeutic areas, with recent work particularly focused on cancer immunotherapy, vaccine development (including mRNA vaccines for lung cancer and melanoma), and nanotherapies for liver conditions. Her research bridges nanotechnology with clinical applications, showing particular strength in translating laboratory discoveries into potential therapeutic solutions for cancer, inflammatory diseases, and vaccine delivery. ICREA Academia award recipient h-index of 20 with over 3,000 citations Principal investigator on numerous research projects including CHIMERNA, TumorOut, ZwiRNA, LIVENANO, and COVINANOVAX As an academic leader, Dr. Fornaguera mentors a large team of researchers including multiple postdoctoral researchers, PhD candidates, and MSc students. She has secured substantial research funding for projects related to mRNA vaccines, cancer nanotherapy, and biomaterials development. Her GEMAT research group has been instrumental in developing innovative approaches for cancer treatment, vaccine delivery, and biomaterial applications, with several projects reaching preclinical stages. The group actively participates in international collaborations and has contributed significantly to the development of the Spanish COVID-19 vaccine.

• Ouabain
• Hypertension
• Kidney Failure
• +6 more

John M. Hamlyn, PhD is a Professor in the Department of Pharmacology & Physiology at the University of Maryland School of Medicine. A full member of the Graduate School and faculty in the NIH Integrative Membrane Biology training program, his career spans from biochemistry to physiology with focus on blood pressure regulation mechanisms. Originally from Britain, he earned his PhD from Glasgow Caledonia University in 1979 followed by postdoctoral work at University of Rochester. His research centers on endogenous ouabain - a steroid hormone he discovered that regulates long-term blood pressure through sodium pump interactions. Current work investigates ouabain's role in acute kidney injury and brain 'chemical clouds' (ouabain, aldosterone, opiates) that modulate neural function. Key methodologies include chromatography, mass spectrometry, animal hemodynamics, and molecular signaling techniques. Analysis of recent publications reveals expanding clinical applications: 40% focus on kidney injury biomarkers, 30% on hypertension genetics (lanosterol synthase polymorphisms), and 20% on brain-aldosterone-ouabain pathways. Notable collaborations include Paolo Manunta (Milan), Frans Leenen (Ottawa), and Michael Blaustein. Major discovery : Endogenous ouabain as first identified mammalian sodium pump inhibitor (1991 PNAS paper) Paradigm shift : Brain 'chemical clouds' concept redefining neural hormone distribution Clinical impact : Preoperative ouabain levels predicting cardiac surgery kidney injury His lab trains numerous graduate students and maintains active collaborations across neurology, cardiology, and nephrology. Current research integrates molecular mechanisms with clinical outcomes in hypertension, heart failure, and kidney disease through both experimental models and human trials.